Eli Lilly and Company (LLY)
$
737.67
+15.10 (2.05%)
Key metrics
Financial statements
Free cash flow per share
0.5421
Market cap
684.8 Billion
Price to sales ratio
13.9747
Debt to equity
2.4432
Current ratio
1.3723
Income quality
0.8389
Average inventory
8.5 Billion
ROE
0.7692
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Eli Lilly and Company, established in 1876 and headquartered in Indianapolis, Indiana, discovers, develops, and markets human pharmaceuticals globally. The total costs and expenses for the company are $27,541,000,000.00 reflecting its overall spending on research, development, and various operational activities. The operating income ratio is 0.29 indicating the company's operational profitability margin, showcasing its capacity to manage costs in relation to income generated. Its operational expenses amount to $19,584,400,000.00 encompassing the various costs incurred in pursuing its business objectives. Additionally, the gross profit ratio is 0.81 reflecting the efficiency of the company's production and sales operations amid its diverse product portfolio, which includes treatments for diabetes, various cancers, autoimmune conditions, and mental health disorders. Notable products such as Basaglar, Humalog, Jardiance, Alimta, and Taltz emphasize Lilly's broad impact across multiple therapeutic areas. The diluted EPS is $11.71 accounting for potential share dilution, which is an essential consideration for investors assessing the company's financial health and profitability. In the financial markets, the stock is priced at $722.57 positioning it in the higher-end market and reflecting investor confidence. It has a high average trading volume of 4,203,419.00 indicating strong liquidity that is desirable for both retail and institutional investors. With a large market capitalization of $699,116,415,120.00 the company is a dominant player in the pharmaceutical space, influencing trends and developments within the industry. Eli Lilly is a key player in the Drug Manufacturers - General industry, contributing significantly to the overall market landscape through innovative therapies and clinical advancements. Furthermore, it belongs to the Healthcare sector, driving innovation and growth while collaborating with various pharmaceutical and biotechnology firms, which strengthens its position in a competitive environment. The combination of a robust product portfolio and a strategic focus on emerging therapies places Eli Lilly in a favorable position for future success while continuing to meet the evolving needs of patients across the globe.
Is Eli Lilly and Company (LLY) a good investment?
Investing in Eli Lilly and Company (LLY) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B, with a Bearish outlook. Always conduct your own research before investing.
What is Eli Lilly and Company (LLY)'s stock forecast?
Analysts predict Eli Lilly and Company stock to fluctuate between $677.09 (low) and $972.53 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Eli Lilly and Company's market capitalization?
As of 2025-05-30, Eli Lilly and Company's market cap is $699,116,415,120, based on 947,736,000 outstanding shares.
How does Eli Lilly and Company compare to competitors like Johnson & Johnson?
Compared to Johnson & Johnson, Eli Lilly and Company has a Higher Market-Cap, indicating a difference in performance.
Does Eli Lilly and Company pay dividends?
Eli Lilly and Company pays dividends. The current dividend yield is 0.74%, with a payout of $1.50 per share.
How can I buy Eli Lilly and Company (LLY) stock?
To buy Eli Lilly and Company (LLY) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for LLY. Place an order (Market, Limit, etc.).
What is the best time to invest in Eli Lilly and Company?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Eli Lilly and Company stock ever split?
Eli Lilly and Company's last stock split was 2:1 on 1997-10-16.
How did Eli Lilly and Company perform in the last earnings report?
Revenue: $45,042,700,000 | EPS: $11.76 | Growth: 101.72%.
Where can I find Eli Lilly and Company's investor relations reports?
Visit https://www.lilly.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Eli Lilly and Company?
You can explore historical data from here
What is the all-time high and low for Eli Lilly and Company stock?
All-time high: $972.53 (2024-08-22) | All-time low: $178.58 (2021-04-28).
What are the key trends affecting Eli Lilly and Company stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
marketbeat.com
Eli Lilly NYSE: LLY has transformed from a steady pharmaceutical giant into one of Wall Street's standout growth stories—and it's not just hype. Powered by blockbuster drugs for diabetes and weight loss, a deep pipeline of next-generation treatments, and aggressive investment in future capacity, Lilly is rewriting what long-term success looks like in Big Pharma.
wsj.com
Novo Nordisk's weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly's Zepbound, and now the company is trying to get back on track.
zacks.com
LLY inks $1B deal to acquire SiteOne, adding phase II-ready pain drug STC-004 to strengthen its neuroscience pipeline.
proactiveinvestors.com
Eli Lilly and Co (NYSE:LLY) announced it is acquiring SiteOne Therapeutics, a private biotech firm developing small-molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders, for up to $1 billion. This includes the acquisition of STC-004, a Nav1.8 inhibitor being studied for the treatment of pain.
benzinga.com
Eli Lilly And Co LLY on Tuesday agreed to acquire SiteOne Therapeutics, Inc., a private biotechnology company developing small-molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders.
fool.com
Eli Lilly's (LLY -0.12%) share price soared during the first Trump administration. That momentum continued with Joe Biden in the White House.
prnewswire.com
INDIANAPOLIS , May 22, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of imlunestrant, an investigational oral selective estrogen receptor degrader (SERD), olomorasib, an investigational KRAS G12C inhibitor, LY4170156, an investigational antibody-drug conjugate (ADC) targeting folate receptor alpha (FRα) and Verzenio® (abemaciclib; a CDK4/6 inhibitor) will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 - June 3 in Chicago. Presentation Highlights Imlunestrant (investigational oral SERD) In an oral presentation, Lilly will share patient-reported outcomes (PROs) from the Phase 3 EMBER-3 trial in patients with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC), and a poster presentation will feature expanded EMBER-3 safety analyses.
prnewswire.com
The authorization in Australia is for adult patients who are Apolipoprotein E- ε 4 heterozygotes or non-carriers INDIANAPOLIS , May 21, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the Australian Therapeutic Goods Administration (TGA) has granted marketing authorization for Kisunla (donanemab), an injection for intravenous infusion every four weeks to treat mild cognitive impairment and mild dementia due to Alzheimer's disease in adults who are Apolipoprotein E ε4 (ApoE ε 4) heterozygotes or non-carriers. Kisunla is the first amyloid-targeting therapy for people with Alzheimer's registered in Australia and the only amyloid plaque-targeting therapy with evidence to support stopping therapy when amyloid plaques are removed.
cnbc.com
Novo Nordisk is banking on fresh leadership to help it reclaim the crown in the booming weight loss drug market. The Danish drugmaker last week abruptly announced that longtime CEO Lars Fruergaard Jorgensen is stepping down, as its obesity injection Wegovy loses ground to Eli Lilly's rival treatment, Zepbound.
fool.com
Eli Lilly (LLY 3.47%) has a strong pipeline of new medicines that could increase the stock price.
See all news
